Navigation Links
Christopher Brennan Joins PharmaNet Development Group as General Counsel

PRINCETON, N.J., Sept. 22 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Christopher S. Brennan has joined the Company as general counsel.

"We are very pleased to have Chris join the PharmaNet Development Group management team," commented Jeffrey P. McMullen, president and chief executive officer. "His diversified experience and expertise will bring valuable insight to the Company and support our growth strategies."

Previously, Mr. Brennan held the position of general counsel at a specialty pharmaceutical company and worked in private practice as a corporate transactional attorney at two prominent, multi-national law firms -- Cravath, Swaine & Moore LLP and Dechert LLP. While at these two global law firms, Mr. Brennan worked along side management teams from various Fortune 500 companies while helping them to successfully undertake and complete company "mission critical" transactions in the areas of mergers and acquisitions, corporate financing, joint ventures, licensing, corporate partnering, private financing and public securities -- all primarily in the pharmaceutical and emerging life science market place.

Mr. Brennan graduated from Fordham University School of Law with honors. For the five years prior to entering law school, he managed multi-million dollar, high-technology projects and led large project teams from various disciplines as a Captain in the United States Air Force.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842

SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
2. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
3. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
4. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
7. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
8. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
9. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
10. DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice
11. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):